Insight Molecular Diagnostics Inc. Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
Insight Molecular Diagnostics Inc. (IMDX) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of -$527.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2018-04-02
- Insight Molecular Diagnostics Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2017 was -$527.00K.
- Insight Molecular Diagnostics Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2016 was -$304.00K, a 505.33% decline from fiscal 2015.
- Insight Molecular Diagnostics Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2015 was $75.00K.
- Insight Molecular Diagnostics Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2014 was -$21.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | -$527.00K 10-K · filed 2018-04-02 |
| 2016-12-31 | -$304.00K 10-K · filed 2018-04-02 |
| 2015-12-31 | $75.00K 10-K · filed 2018-04-02 |
| 2014-12-31 | -$21.00K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |